Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pravastatin Sodium

FDA-approved product (tablet, oral), marketed as Pravachol, Pravastatin Sodium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pravastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atherosclerosis
  • Cardiovascular disease
  • Coronary artery disease
  • Coronary atherosclerosis
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pravastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pravastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial)

    NCT07098975 · start 2026-01-14

    Registered record
    Registry ID
    NCT07098975
    Conditions
    Preeclampsia (PE); Intrauterine Growth Restriction (IUGR); Placental Insufficiency
    Interventions
    Pravastatin 40 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-14
    Completion
    2028-07
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreeclampsia (PE); Intrauterine Growth Restriction (IUGR); Placental Insufficiency
    InterventionPravastatin 40 mg; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Novel Treatment of Radiation Associated Dysphagia With Statins

    NCT07217938 · start 2025-12-05

    Registered record
    Registry ID
    NCT07217938
    Conditions
    Radiation-associated Dysphagia; Head &Amp; Neck Cancer
    Interventions
    Pravastatin 40 Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-05
    Completion
    2028-10-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRadiation-associated Dysphagia; Head &Amp; Neck Cancer
    InterventionPravastatin 40 Mg Oral Tablet
    PhasePhase 2
    Registry statusRecruiting

  • Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy

    NCT06553157 · start 2024-09-01

    Registered record
    Registry ID
    NCT06553157
    Conditions
    Solid Tumors; Ototoxicity
    Interventions
    Statin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2024-09-01
    Completion
    2025-10-01
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors; Ototoxicity
    InterventionStatin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins

    NCT06262685 · start 2024-03-04

    Registered record
    Registry ID
    NCT06262685
    Conditions
    Cardiovascular Diseases; Dyslipidemias; Statin Adverse Reaction; Pharmacogenic Myopathy
    Interventions
    Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines; Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines; Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines; Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines; Standard of Care (SoC) dosing of atorvastatin; Standard of Care (SoC) dosing of simvastatin; Standard of Care (SoC) dosing of pitavastatin; Standard of Care (SoC) dosing of rosuvastatin; Standard of Care (SoC) dosing of prasavastatin; Standard of Care (SoC) dosing of lovastatin; Standard of Care (SoC) dosing of fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-03-04
    Completion
    2025-03-04
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Dyslipidemias; Statin Adverse Reaction; Pharmacogenic Myopathy
    InterventionPreemptive pharmacogenetic atorvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines; Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines; Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines +10 more
    PhasePhase 4
    Registry statusUnknown

  • Detoxification From the Lipid Tract

    NCT06357104 · start 2024-02-26

    Registered record
    Registry ID
    NCT06357104
    Conditions
    COVID-19 Vaccine Adverse Reaction
    Interventions
    electroencephalogram biofeedback; electrical brain stimulation; ultra-low frequency transcranial magnetic stimulation; Sertraline Hydrochloride; Clonazepam; Alprazolam; Metoprolol; Olanzapine; Pravastatin Sodium 20 MG; Sacubitril Valsartan Sodium Hydrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-02-26
    Completion
    2024-03-20
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Vaccine Adverse Reaction
    Interventionelectroencephalogram biofeedback; electrical brain stimulation; ultra-low frequency transcranial magnetic stimulation; Sertraline Hydrochloride +6 more
    PhasePhase 4
    Registry statusCompleted

  • Real World Evidence Study of Statin Use in Brazil

    NCT05285085 · start 2021-11-19

    Registered record
    Registry ID
    NCT05285085
    Conditions
    Cardiovascular Diseases; Myocardial Infarction; Stroke; Hypertension; Diabetes Mellitus; Dyslipidemias
    Interventions
    Statin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-11-19
    Completion
    2021-12-15
    Enrolment
    2,133,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Myocardial Infarction; Stroke; Hypertension +2 more
    InterventionStatin
    PhaseNot recorded
    Registry statusCompleted

  • Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

    NCT04640571 · start 2021-04-01

    Registered record
    Registry ID
    NCT04640571
    Conditions
    Bile Salt Export Pump (BSEP) Transporter; Polysorbate 80
    Interventions
    pravastatin and chenodeoxycholic acid, after metformin and placebo; valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2021-11-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBile Salt Export Pump (BSEP) Transporter; Polysorbate 80
    Interventionpravastatin and chenodeoxycholic acid, after metformin and placebo; valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
    PhasePhase 4
    Registry statusCompleted

  • A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer

    NCT04385433 · start 2020-12-04

    Registered record
    Registry ID
    NCT04385433
    Conditions
    Breast Cancer
    Interventions
    EXPERIMENTAL ARM; CONTROL GROUP; Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-12-04
    Completion
    2023-04-27
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionEXPERIMENTAL ARM; CONTROL GROUP; Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)
    PhasePhase 3
    Registry statusTerminated

  • Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

    NCT04190433 · start 2020-09-01

    Registered record
    Registry ID
    NCT04190433
    Conditions
    Breast Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Lymphoma; Sarcoma
    Interventions
    Carvedilol; Lisinopril; Pravastatin; Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-09-01
    Completion
    2023-04-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Lymphoma; Sarcoma
    InterventionCarvedilol; Lisinopril; Pravastatin; Spironolactone
    PhasePhase 2
    Registry statusWithdrawn

  • Statin Adjunctive Therapy for TB

    NCT03456102 · start 2020-03-09

    Registered record
    Registry ID
    NCT03456102
    Conditions
    Tuberculosis
    Interventions
    Pravastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-03-09
    Completion
    2022-08-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPravastatin
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects

    NCT04092751 · start 2019-11-22

    Registered record
    Registry ID
    NCT04092751
    Conditions
    Pharmacokinetics
    Interventions
    PRA; SCY-078 plus PRA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-11-22
    Completion
    2019-12-20
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionPRA; SCY-078 plus PRA
    PhasePhase 1
    Registry statusCompleted

  • Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

    NCT03947385 · start 2019-06-28

    Registered record
    Registry ID
    NCT03947385
    Conditions
    Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors
    Interventions
    IDE196; Binimetinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2019-06-28
    Completion
    2027-06-15
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors
    InterventionIDE196; Binimetinib; Crizotinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

    NCT03510884 · start 2018-05-31

    Registered record
    Registry ID
    NCT03510884
    Conditions
    Hypercholesterolaemia
    Interventions
    Alirocumab SAR236553 (REGN727); Rosuvastatin; Atorvastatin; Simvastatin; Pravastatin; Lovastatin; Fluvastatin; Ezetimibe; Cholestyramine; Nicotinic acid; Fenofibrate; Omega-3 fatty acids; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-31
    Completion
    2022-08-05
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolaemia
    InterventionAlirocumab SAR236553 (REGN727); Rosuvastatin; Atorvastatin; Simvastatin +9 more
    PhasePhase 3
    Registry statusCompleted

  • Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

    NCT03131973 · start 2017-05-13

    Registered record
    Registry ID
    NCT03131973
    Conditions
    Rheumatoid Arthritis
    Interventions
    BMS-986195; Methotrexate; Leucovorin; Caffeine; Montelukast; Flurbiprofen; Omeprazole; Midazolam; Digoxin; Pravastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-13
    Completion
    2017-11-10
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionBMS-986195; Methotrexate; Leucovorin; Caffeine +6 more
    PhasePhase 1
    Registry statusCompleted

  • Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

    NCT02484261 · start 2015-05

    Registered record
    Registry ID
    NCT02484261
    Conditions
    Leukemia
    Interventions
    Bortezomib; Pravastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2015-05
    Completion
    Not recorded
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionBortezomib; Pravastatin
    PhasePhase 1
    Registry statusTerminated